Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer.
暂无分享，去创建一个
N. Schultz | D. Solit | W. Chatila | Lilan Ling | Y. Janjigian | G. Ku | J. Hechtman | R. Ptashkin | T. Merghoub | R. Do | N. Pandit-Taskar | D. Ilson | V. Paroder | S. Maron | R. Nagy | H. Walch | M. Simmons | Shalom Sabwa